Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
HANGZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tras la exitosa finalización de un riguroso desafío de conducción en Melbourne y Sídney entre el 9 y el 10 de diciembre de 2025, Geely Auto se...
-
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI...
-
北京, Dec. 16, 2025 (GLOBE NEWSWIRE) -- BOSS直聘 (Nasdaq: BZ; HKEX: 2076) 今日公告顯示，公司繼續推進股份回購計劃，耗資逾3,500萬元人民幣回購約50萬股普通股。BOSS直聘持續回饋股東，於今年10月完成約8,000萬美元的年度分紅。根據現有回購計劃，截止2026年8月底，BOSS直聘可回購最多為2.5億美元的股份。...
-
MELBOURNE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Geely Auto anunció oficialmente que su modelo híbrido enchufable global, el Geely STARRAY EM-i (también conocido como Geely EX5 EM-i en...
-
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an...
-
MELBOURNE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Geely Auto officially announced that its global plug-in hybrid model, the Geely STARRAY EM-i (also known as Geely EX5 EM-i in some markets),...
-
Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
-
SHENZHEN, CHINA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of...
-
In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%.
-
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Mr. Phil Yu...